Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Chosa

    MCap

    SEK57m

    Last close

    SEK0.80

    ▲ 0.20 (33.33%)

    Vection Technologies

    MCap

    AUD47m

    Last close

    AUD0.04

    ▲ 0.00 (12.90%)

    Metro Bank

    MCap

    GBP684m

    Last close

    GBP1.02

    ▲ 7.90 (8.43%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Basilea Pharmaceutica – executive interview

Basilea Pharmaceutica – executive interview

Basilea Pharmaceutica — 9 videos in collection

More on this equity

Basilea Pharmaceutica is a Switzerland-based biopharmaceutical company, established in 2000 as a spin-out from Roche with the divestment of its anti-infective portfolio. It is listed on the SIX Swiss Stock Exchange and recently announced plans to focus strategically on anti-infectives. Revenue growth will continue to be driven from its two marketed anti-infectives, Cresemba (antifungal, for invasive mould infections) and Zevtera (antibiotic, for hospital infections). Currently, Cresemba is commercialised globally through partners such as Pfizer and Astellas. Basilea also announced plans to monetise its oncology assets (derazantinib, a pan-FGFR kinase inhibitor and lisavanbulin, a potential novel checkpoint inhibitor), which will free up resources and provide the company with incremental (financial) flexibility to fund its anti-infective strategy.

In this video, CEO David Veitch discusses the company’s anti-infective strategy.

< Previous
Next >

You may also be interested in these:

Healthcare

Interview with David Veitch, CEO of Basilea Pharmaceutica

Edison's most frequently asked questions - Basilea Pharmaceutica

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free